Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03033927 · ClinicalTrials.gov registry record
Predicting Effective Therapy in Pancreatic Cancer
A clinical trial of Pancreatic Cancer and Pancreatic Adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- 74
- Enrollment target
- 4
- Study locations
NCT03033927 is a study of Pancreatic Cancer and Pancreatic Adenocarcinoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 74 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (81% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT03033927, a study of Pancreatic Cancer and Pancreatic Adenocarcinoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 74 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this phase II study is to develop a test to predict response of pancreatic cancer to different chemotherapy regimens.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST CTC isolocation and analysis
Study Locations (4)
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Cancer Center Basking Ridge - Basking Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2017-01-24 |
| Est. Completion | 2026-01-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03033927
The ClinicalTrials.gov registry entry for NCT03033927 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (81% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which CTC isolocation and analysis is the first listed.
NCT03033927 reports 4 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT03033927 about?
NCT03033927 is a clinical study titled "Predicting Effective Therapy in Pancreatic Cancer". The purpose of this phase II study is to develop a test to predict response of pancreatic cancer to different chemotherapy regimens.
What is the current status of trial NCT03033927?
This trial is currently active not recruiting. The enrollment target is 74 participants. The study started on 2017-01-24. Estimated completion is 2026-01-24.
What conditions does trial NCT03033927 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT03033927?
The interventions under investigation include: CTC isolocation and analysis (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03033927?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03033927 being conducted?
This trial has 4 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.